Anti-Tumor Effect of IDF-11774, an Inhibitor of Hypoxia-Inducible Factor-1, on Melanoma |
Kim, Nan-Hyung
(Department of Dermatology, Dongguk University Ilsan Hospital)
Jeong, Jong Heon (Department of Dermatology, Dongguk University Ilsan Hospital) Park, Yu Jeong (Department of Dermatology, Dongguk University Ilsan Hospital) Shin, Hui Young (Department of Dermatology, Dongguk University Ilsan Hospital) Choi, Woo Kyoung (Department of Dermatology, Dongguk University Ilsan Hospital) Lee, Kyeong (BK21 FOUR Team and Integrated Research Institute for Drug Development, College of Pharmacy, Dongguk University) Lee, Ai-Young (Department of Dermatology, Dongguk University Ilsan Hospital) |
1 | Barsoum, I. B., Smallwood, C. A., Siemens, D. R. and Graham, C. H. (2014) A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells. Cancer Res. 74, 665-674. |
2 | Cheli, Y., Giuliano, S., Fenouille, N., Allegra, M., Hofman, V., Hofman, P., Bahadoran, P., Lacour, J., Tartare-Deckert, S., Bertolotto, C. and Ballotti, R. (2012) Hypoxia and MITF control metastatic behaviour in mouse and human melanoma cells. Oncogene 31, 2461-2470. DOI |
3 | D'Aguanno, S., Mallone, F., Marenco, M., Del Bufalo, D. and Moramarco, A. (2021) Hypoxia-dependent drivers of melanoma progression. J. Exp. Clin. Cancer Res. 40, 159. |
4 | Gonzalez-Ruiz, L., Gonzalez-Moles, M. A., Gonzalez-Ruiz, I., Ruiz-Avila, I. and Ramos-Garcia, P. (2021) Prognostic and clinicopathological significance of CCND1/cyclin D1 upregulation in melanomas: a systematic review and comprehensive meta-analysis. Cancers 13, 1314. |
5 | Kedinger, V., Meulle, A., Zounib, O., Bonnet, M.-E., Gossart, J.-B., Benoit, E., Messmer, M., Shankaranarayanan, P., Behr, J.-P., Erbacher, P. and Bolcato-Bellemin, A. L. (2013) Sticky siRNAs targeting survivin and cyclin B1 exert an antitumoral effect on melanoma subcutaneous xenografts and lung metastases. BMC Cancer 13, 338. |
6 | Nowak-Stepniowska, A., Osuchowska, P. N., Fiedorowicz, H. and Trafny, E. A. (2022) Insight in hypoxia-mimetic agents as potential tools for mesenchymal stem cell priming in regenerative medicine. Stem Cells Int. 2022, 8775591. |
7 | Pearlman, R. L., de Oca, M. K. M., Pal, H. C. and Afaq, F. (2017) Potential therapeutic targets of epithelial-mesenchymal transition in melanoma. Cancer Lett. 391, 125-140. DOI |
8 | Zou, M. Z., Liu, W. L., Li, C. X., Zheng, D. W., Zeng, J. Y., Gao, F., Ye, J. J. and Zhang, X. Z. (2018) A multifunctional biomimetic nanoplatform for relieving hypoxia to enhance chemotherapy and inhibit the PD-1/PD-L1 axis. Small 14, 1801120. |
9 | Dratkiewicz, E., Simiczyjew, A., Mazurkiewicz, J., Zietek, M., Matkowski, R. and Nowak, D. (2021) Hypoxia and extracellular acidification as drivers of melanoma progression and drug resistance. Cells 10, 862. |
10 | Koch, A., Ebert, E. V., Seitz, T., Dietrich, P., Berneburg, M., Bosserhoff, A. and Hellerbrand, C. (2020) Characterization of glycolysis-related gene expression in malignant melanoma. Pathol. Res. Pract. 216, 152752. |
11 | Singh, M., Agarwal, S., Agarwal, V., Mall, S., Pancham, P. and Mani, S. (2021) Current theranostic approaches for metastatic cancers through hypoxia-induced exosomal packaged cargo. Life Sci. 286, 120017. |
12 | Ban, H. S., Kim, B.-K., Lee, H., Kim, H. M., Harmalkar, D., Nam, M., Park, S.-K., Lee, K., Park, J.-T., Kim, I., Lee, K., Hwang, G. S. and Won, M. (2017) The novel hypoxia-inducible factor-1α inhibitor IDF-11774 regulates cancer metabolism, thereby suppressing tumor growth. Cell Death Dis. 8, e2843. |
13 | Pio, R., Ajona, D., Ortiz-Espinosa, S., Mantovani, A. and Lambris, J. D. (2019) Complementing the cancer-immunity cycle. Front. Immunol. 10, 774. |
14 | Rebecca, V. W., Somasundaram, R. and Herlyn, M. (2020) Pre-clinical modeling of cutaneous melanoma. Nat. Commun. 11, 2858. |
15 | Schadendorf, D., van Akkooi, A. C., Berking, C., Griewank, K. G., Gutzmer, R., Hauschild, A., Stang, A., Roesch, A. and Ugurel, S. (2018) Melanoma. Lancet 392, 971-984. DOI |
16 | Shrayer, D., Bogaars, H., Gersten, D., Hearing, V., Maizel, A. and Wanebo, H. (1994) Nude mouse model to study passive humoral immunotherapy directed against B16 F10 murine melanoma. J. Surg. Oncol. 57, 50-56. DOI |
17 | Tchakarska, G. and Sola, B. (2020) The double dealing of cyclin D1. Cell Cycle 19, 163-178. DOI |
18 | Tittarelli, A., Navarrete, M., Lizana, M., Hofmann-Vega, F. and Salazar-Onfray, F. (2020) Hypoxic melanoma cells deliver microRNAs to dendritic cells and cytotoxic T lymphocytes through connexin-43 channels. Int. J. Mol. Sci. 21, 7567. |
19 | Van Duijn, A., Willemsen, K. J., Van Uden, N. O., Hoyng, L., Erades, S., Koster, J., Luiten, R. M. and Bakker, W. J. (2022) A secondary role for hypoxia and HIF1 in the regulation of (IFNγ-induced) PD-L1 expression in melanoma. Cancer Immunol. Immunother. 71, 529-540. DOI |
20 | Mahmoud, F., Shields, B., Makhoul, I., Avaritt, N., Wong, H. K., Hutchins, L. F., Shalin, S. and Tackett, A. J. (2017) Immune surveillance in melanoma: from immune attack to melanoma escape and even counterattack. Cancer Biol. Ther. 18, 451-469. DOI |
21 | Nam, M.-W., Kim, C.-W. and Choi, K.-C. (2022) Epithelial-mesenchymal transition-inducing factors involved in the progression of lung cancers. Biomol. Ther. (Seoul) 30, 213-220. DOI |
22 | Kim, H. J., Choi, W. J. and Lee, C. H. (2015) Phosphorylation and reorganization of keratin networks: Implications for carcinogenesis and epithelial mesenchymal transition. Biomol. Ther. (Seoul) 23, 301-312. DOI |
23 | Liu, A. and Curran, M. A. (2020) Tumor hypermetabolism confers resistance to immunotherapy. Semin. Cancer Biol. 65,155-163. DOI |
24 | Malekan, M., Ebrahimzadeh, M. A. and Sheida, F. (2021) The role of Hypoxia-Inducible Factor-1alpha and its signaling in melanoma. Biomed. Pharmacother. 141, 111873. |
25 | Michaylira, C. Z. and Nakagawa, H. (2006) Hypoxic microenvironment as a cradle for melanoma development and progression. Cancer Biol. Ther. 5, 476-479. DOI |
26 | Li, Y., Patel, S. P., Roszik, J. and Qin, Y. (2018) Hypoxia-driven immunosuppressive metabolites in the tumor microenvironment: new approaches for combinational immunotherapy. Front. Immunol. 9, 1591. |
27 | Martinez-Garcia, M. A., Riveiro-Falkenbach, E., Rodriguez-Peralto, J. L., Nagore, E., Martorell-Calatayud, A., Campos-Rodriguez, F., Farre, R., Hernandez Blasco, L., Banuls Roca, J., Chiner Vives, E., Sanchez-de-la-Torre, A., Abad Capa, J., Montserrat, J. M., Almendros, I., Perez-Gil, A., Cabriada Nuno, V., Cano-Pumarega, I., Corral Penafiel, J., Diaz Cambriles, T., Mediano, O., Dalmau Arias, J. and Gozal, D.; Spanish Sleep Network (2017) A prospective multicenter cohort study of cutaneous melanoma: clinical staging and potential associations with HIF-1α and VEGF expressions. Melanoma Res. 27, 558-564. DOI |
28 | Munoz-Sanchez, J. and Chanez-Cardenas, M. E. (2019) The use of cobalt chloride as a chemical hypoxia model. J. Appl. Toxicol. 39, 556-570. DOI |
29 | Vandyck, H. H., Hillen, L. M., Bosisio, F. M., van den Oord, J., Zur Hausen, A. and Winnepenninckx, V. (2021) Rethinking the biology of metastatic melanoma: a holistic approach. Cancer Metastasis Rev. 40, 603-624. DOI |